Creative Biolabs has established a comprehensive in vitro diagnostic (IVD) platform that allows us to offer customized antibody development services against several disease markers to our clients. Here, we introduce our IVD antibody development services targeting the placental growth factor (PlGF) marker of coronary artery disease (CAD).

PlGF is a member of the vascular endothelial growth factor (VEGF) family, which was initially found in the placenta, but was also discovered in a variety of other tissues. This protein is released as a glycosylated homodimer and the most widely known structural feature of PlGF is due to six cysteine residues of each monomer which form three intra-chain disulfide bonds, forming a special three-dimensional structure known as cystine-knot motif. PlGF serves a crucial role in a number of physiological and pathological situations, such as cardiovascular diseases (CVD), tumour progression and preeclampsia. It is a multitasking cytokine that enables to excite angiogenesis through direct or indirect mechanisms on account of its capacity to bind and activate VEGFR-1 receptor expressed in a number of cell types. PlGF seems to be stable in circulation and may be a powerful candidate as a biomarker for myocardial ischemia, plaque instability, and prognosis for patients with acute coronary syndrome (ACS).

IVD Antibodies for Placental Growth Factor (PlGF) Marker Figure 1. Schematic diagram of the indirect and direct angiogenic influences of PlGF and vascular endothelial growth factor B (VeGFB) on endothelial cells. PlGF indirectly excites angiogenesis through recruiting and activating a variety of cell types which upregulate VEGFA and other angiogenic factors, for example, stromal cell-derived factor 1 (SDF1), matrix metalloproteinase 9 (MMP9) and interleukin 8 (IL8). (Fischer, C. 2008)

PlGF Marker of Coronary Artery Disease

CAD, a most usual type of heart disease, is the primary cause of death in the United States. It occurs when the arteries that offer blood to heart muscle turn into hardened and narrowed. This is on account of the buildup of cholesterol and other material on the inner walls of arteries, and this buildup is known as atherosclerosis. Besides, CAD is able to weaken the heart muscle and resulting in heart failure and arrhythmias. Animal data reveals that PlGF is able to play as an early and major inflammatory instigator of atherosclerotic plaque instability. PlGF also acts an important role in predicting mortality and cardiovascular events in ESRD (end-stage renal disease) patients on dialysis. In addition, increased PlGF concentration is an independent biomarker of short term and long-term adverse outcome in patients with suspicious acute coronary syndrome (ACS). In the CAPTURE research, patients with ACS had increased PlGF levels contrasted to patients with noncardiac chest pain or stable angina.

IVD Antibodies for Placental Growth Factor (PlGF) Marker Figure 2. Graph shows the performance of PlGF, troponin T, high-sensitive troponin T, and soluble Fms-like tyrosine kinase 1 in the operating characteristic curves for the diagnosis of acute myocardial infarction. (Hochholzer, W. 2011)

IVD Antibody Development Services for PIGF Marker

Biomarkers are usually proteins that can be detected in different biological samples to offer independent diagnostic and prognostic value by presenting an underlying disease state. As an inflammatory biomarker of CAD, PlGF has a promising role for the forecast of risk for developing CAD and is highly connected with the severity of CAD. At Creative Biolabs, we offer customized IVD antibody development services targeting PIGF marker to provide high-quality antibodies to contribute to the success of your IVD project.

With years of devotion and accumulation in this particular field, Creative Biolabs is confident in offering you the best products and services. Please feel free to contact us for more information and a formal quote.


  1. Fischer, C. (2008). “FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?.” Nature Reviews Cancer 8(12), 942-956.
  2. Matsui, M. (2015). “Placental Growth Factor as a Predictor of Cardiovascular Events in Patients with CKD from the NARA-CKD Study.” Journal of the American Society of Nephrology ASN-2014080772.
  3. Hochholzer, W. (2011). “Impact of soluble fms-like tyrosine kinase-1 and placental growth factor serum levels for risk stratification and early diagnosis in patients with suspected acute myocardial infarction.” European heart journal 32(3), 326-335.

For lab research use only.

Online Inquiry

*E-mail Address:
*Service & Products Interested:
Project Description:

Contact Us




Follow us on:
Copyright © 2021 Creative Biolabs.
Inquiry Basket